Autolus Therapeutics plc (AUTL)
Market Cap | 372.08M |
Revenue (ttm) | 2.72M |
Net Income (ttm) | -163.55M |
Shares Out | 173.06M |
EPS (ttm) | -1.85 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,260,963 |
Open | 2.02 |
Previous Close | 1.99 |
Day's Range | 1.96 - 2.15 |
52-Week Range | 1.60 - 5.04 |
Beta | 1.56 |
Analysts | Buy |
Price Target | 8.64 (+301.86%) |
Earnings Date | Mar 9, 2023 |
About AUTL
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; ... [Read more]
Financial Performance
In 2021, AUTL's revenue was $2.33 million, an increase of 35.86% compared to the previous year's $1.72 million. Losses were -$142.10 million, 0.00% more than in 2020.
Financial StatementsAnalyst Forecast
According to 17 analysts, the average rating for AUTL stock is "Buy." The 12-month stock price forecast is $8.64, which is an increase of 301.86% from the latest price.
News

Autolus Therapeutics announces Board changes
LONDON, Jan. 20, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announces two chan...

Autolus Announces Partial Exercise of Underwriters' Option to Purchase Additional ADSs
LONDON, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced today th...

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2022
LONDON, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces th...

Autolus Announces Pricing of Public Offering
LONDON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced th...

Autolus Announces Proposed Public Offering in the United States
LONDON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced th...

Autolus Therapeutics to Receive $70 Million in Milestone Payments from Blackstone Life Sciences
LONDON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces th...

Autolus Therapeutics announces pivotal Phase 2 FELIX clinical trial has met primary endpoint at interim analysis
LONDON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces th...

Autolus Therapeutics to Present Three Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2022
LONDON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces th...

Autolus Therapeutics Reports Third Quarter 2022 Financial Results and Operational Progress
LONDON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced it...

Autolus Therapeutics to Report Third Quarter 2022 Financial Results on November 3, 2022
LONDON, Oct. 21, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced th...

Moderna exercises option to license proprietary targeting technology from Autolus
- Option exercised on undisclosed immune-oncology target following evaluation period by Moderna -

Autolus Therapeutics Announces Collaboration with Bristol Myers Squibb for Use of Autolus' Proprietary Safety Switch System
- Bristol Myers Squibb to receive access to Autolus' RQR8 safety switch for use in cell therapy programs -

Correction - Autolus Therapeutics to Report Second Quarter 2022 Financial Results on August 4, 2022
In the previous version the link to register for the conference call was incorrect – this press release contains the correct link to register for the call, and replaces the earlier version

Autolus Therapeutics to Report Second Quarter 2022 Financial Results on August 4, 2022
LONDON, July 21, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced th...

Autolus Therapeutics to Participate in William Blair's Biotech Focus Conference 2022, New York, July 12 – 13, 2022
LONDON, July 06, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces th...

Autolus Therapeutics Presents Clinical Data Updates at the European Hematology Association Congress
- AUTO4 shows high level of clinical activity with a novel targeting approach for patients with T Cell Lymphoma - AUTO1/22 demonstrates encouraging and durable responses in children ineligible for com...

Autolus to hold Annual General Meeting (AGM) of Shareholders on Tuesday, June 28, 2022
LONDON, May 31, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today posted notice...

Autolus Therapeutics to Participate in the Jefferies Healthcare Conference, being held in New York from June 8 – 10, 2022
LONDON, May 27, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces tha...

Autolus Therapeutics to Present Four Clinical Data Updates at the European Hematology Association Congress
- AUTO4: oral presentation on initial clinical experience in peripheral T cell lymphoma - AUTO1/22: oral presentation on initial experience in r/r pediatric B-cell acute lymphoblastic leukemia - obe-c...

Autolus Therapeutics Reports First Quarter 2022 Financial Results and Operational Progress
- Conference call to be held on May 5, 2022 at 8:30 am ET/1:30 pm BST - - Conference call to be held on May 5, 2022 at 8:30 am ET/1:30 pm BST -

Autolus Therapeutics to Present Three Novel Cell Programming Approaches at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting, May 16-19, 2022
Developing cell programming capabilities to improve our pipeline of precise, controlled and highly active products Developing cell programming capabilities to improve our pipeline of precise, controll...

FDA Grants Regenerative Medicine Advanced Therapy (RMAT) designation to Autolus' CAR T cell therapy, obe-cel, for the treatment of adult B-ALL
LONDON, April 25, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced t...

Autolus Therapeutics to Report First Quarter 2022 Financial Results and Host Conference Call on May 5
LONDON, April 25, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced t...

Autolus Therapeutics Receives EMA Orphan Medical Product Designation for obe-cel for Treatment of Acute Lymphoblastic Leukemia
LONDON, March 31, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced t...

Autolus Therapeutics to Participate in Conferences During April 2022
- Wells Fargo Annual Biotech Forum on April 12 and 13 -